Sunitinib
CAS 557795-19-4 4 FDA-DMF suppliersSmall Molecule
Overview
Sunitinib is an oral, small molecule multi-targeted receptor tyrosine kinase inhibitor that is used to treat cancer. It is known for its efficacy in inhibiting processes that result in tumor growth and cancer metastasis.
Therapeutic areas
OncologyRenal Cell CarcinomaGastrointestinal Stromal Tumors
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.